Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

Chronic Obstructive Pulmonary Disease [COPD] Treatment Market (Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook 2031

  • The global chronic obstructive pulmonary disease (COPD) treatment market was valued at US$ 19.8 Bn in 2021
  • The global market is projected to grow at a CAGR of 4.4% from 2022 to 2031
  • The global chronic obstructive pulmonary disease (COPD) treatment market is anticipated to reach more than US$ 30.4 Bn by the end of 2031

Analysts’ Viewpoint on Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Scenario

Exposure to tobacco smoke, which includes second­hand or passive exposure, allergens (such as pollen, ragweed, dust mites, or animal dander), irritants in the air (such as chemical fumes, smoke, or strong odors), and extreme weather conditions are the major risk factors driving the global chronic obstructive pulmonary disease treatment market. Other risk factors such as indoor air pollution (such as solid fuel used for heating and cooking), outdoor air pollution, occupational dust and chemicals (such as irritants, vapors, and fumes), and frequent lower respiratory infections during childhood are also propelling the global chronic obstructive pulmonary disease treatment market. Key companies operating in the market are focusing on developing low-cost and effective drugs for the treatment of chronic obstructive pulmonary diseases to increase their global footprint.

Chronic Obstructive Pulmonary Disease Treatment Market

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Introduction

Chronic obstructive pulmonary disease is a group of conditions affecting the lungs that lead to difficulty in breathing. Chronic bronchitis and emphysema are the two major types of chronic obstructive pulmonary diseases. Breathlessness is a key characteristic of COPD. In case of emphysema, the alveoli (tiny air sac) in the lungs is damaged. The walls of the alveoli are stretched, making the lungs bigger and resulting in difficulty in the movement of air. In chronic bronchitis, bronchial airways (breathing tubes) inside the lungs are inflamed. High prevalence of COPD across the globe and rich pipeline of drugs for COPD treatment are likely to drive the global market during the forecast period. Furthermore, increase in geriatric population and unhealthy lifestyle choices among various age groups are projected to propel the chronic obstructive pulmonary disease (COPD) treatment market in the near future.

Request a sample to get extensive insights into the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

Rise in Prevalence of COPD Across Globe

Chronic obstructive pulmonary disease (COPD) is a major health concern affecting a large number of people across the globe. The disease burden is rising, thereby increasing the need for COPD management. Tobacco smoking could lead to COPD. The number of adults addicted to smoking has been increasing across the globe. Other risk factors include occupation and indoor air pollution. According to the WHO, the primary cause of COPD is exposure to tobacco smoke (either active smoking or passive smoking). According to the organization, chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, accounting for 3.23 million deaths in 2019. Nearly 90% of COPD deaths in those under 70 years of age occur in low- and middle-income countries (LMIC). According to a report by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) published in 2022, the prevalence and burden of COPD is projected to increase in the near future due to continued exposure to COPD risk factors, rise in incidence of interstitial lung diseases, and aging population across the world. This is anticipated to augment the chronic obstructive pulmonary disease treatment market in the near future.

Increase in Adoption of More Effective Combination Therapy to Drive Global COPD Treatment Market

Combination therapies include LAMA-ICS, LABA-ICS, triple therapy, and other combination drugs. Adoption of combination therapy is increasing, as it is more effective than separate use of bronchodilators and corticosteroids. Increase in the number of patients successfully treated with combination therapy who were not showing signs of recovery with bronchodilators or corticosteroid treatments is expected to fuel the global chronic obstructive pulmonary disease treatment market. Combination therapy is more effective than monotherapy for improving symptoms and quality of life.

Request a custom report on Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

Growth in Success Rate of COPD Treatment to Augment Combination Therapy Segment

In terms of drug class, the global COPD treatment market has been classified into combination therapy, bronchodilators, corticosteroids, phosphodiesterase type 4 inhibitor, mucokinetics, and others. The combination therapy segment held major share of around 50% of the global market in 2021. It is likely to dominate the global market during the forecast period, owing to the increase in efficacy of combination therapy in COPD treatment. Rise in the success rate of combination therapy in COPD treatment and recent regulatory approvals have augmented the adoption of combination therapy. This is projected to drive the segment during the forecast period.

Surge in Airflow Blockage and Breathing Issues among Smokers Fueling Chronic Bronchitis Segment

In terms of type, the global COPD treatment market has been bifurcated into chronic bronchitis and emphysema. The chronic bronchitis segment accounted for the largest chronic obstructive pulmonary disease treatment market share in 2021. Chronic bronchitis is a group of lung diseases that causes airflow blockage and breathing issues. It is widespread among smokers and rising at a rapid pace.

Rise in Number of COPD Therapeutics Dispensed to Boost Retail Pharmacies Segment

Based on distribution channel, the global market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment is anticipated to account for major share of the global chronic obstructive pulmonary disease treatment market during the forecast period. The segment is expected to grow at a rapid pace during the forecast period, owing to the increase in number of COPD therapeutics dispensed through retail pharmacies and rise in number of retail pharmacies in developing countries.

Regional Outlook of Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

As per chronic obstructive pulmonary disease treatment market analysis, North America accounted for the largest share of around 40% of the global market in 2021. The market in the region is projected to grow at a CAGR of 4.3% from 2022 to 2031. This can be ascribed to the highly structured health care industry and availability of well-defined reimbursement policies from private and public health insurance firms. Furthermore, rise in research & development activities to provide advanced and efficient products, and presence of a large number of players are driving the chronic obstructive pulmonary disease treatment market size in North America.

Europe held the second largest share of the global market in 2021. Well-developed health care infrastructure and increase in incidence of chronic obstructive pulmonary diseases are propelling the COPD treatment market in the region.

The market in Asia Pacific is expected to grow at the fastest CAGR of 4.7% during the forecast period. The region has a relatively untapped chronic obstructive pulmonary disease treatment market compared to developed regions. Therefore, Asia Pacific offers significant opportunities to market players. High prevalence of chronic obstructive pulmonary disease, increase in geriatric population, surge in patient population, and growth of the health care industry are propelling the chronic obstructive pulmonary disease treatment market in the region.

Analysis of Key Players in Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

The global chronic obstructive pulmonary disease (COPD) treatment market is consolidated, with the presence of a small number of key players. As per chronic obstructive pulmonary disease treatment market trends, leading players in the market are adopting strategies such as new product development, product launches, product approvals, agreements, partnerships, and mergers. Key players operating in the global chronic obstructive pulmonary disease (COPD) treatment market are Almirall, AstraZeneca, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Kyowa Hakko Kirin, Mylan N.V., Novartis AG, Orion Corporation, Sanofi, Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.), Teva Pharmaceutical Industries Ltd., Theravance Biopharma, and Verona Pharmaceuticals.

Key Developments in Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

  • In January 2022, the first patient was enrolled in a phase 4 study comparing Yupelri (revefenacin) to Spiriva (tiotropium) in improving lung health in adults with severe chronic obstructive pulmonary disease (COPD). The safety of these two approved once-daily COPD maintenance treatments would be assessed as well. Yupelri is a bronchodilator, a type of medication that relaxes and widens the lung airways, making breathing easier. It was developed by Theravance Biopharma and Mylan (now part of Viatris). It is available as an inhalable solution via a nebulizer, a small machine that turns liquid into a fine mist.
  • In November 2021, AstraZeneca announced that it had sold rights to sell Tudorza, also known as Eklira abroad, and Duaklir to the Switzerland-based pharmaceutical company Covis Pharma Group for US$ 270 Mn. These products are indicated for the treatment of chronic obstructive pulmonary disease (COPD).
  • In October 2021, Mylan Pharmaceuticals received the FDA approval for its investigational new drug application (ANDA) for Breyna (budesonide and formoterol fumarate dihydrate inhalation aerosol), the first approved generic version of AstraZeneca's Symbicort. It is anticipated to be available in dosage strengths of 160 mcg/4.5 mcg and 80 mcg/4.5 mcg for patients with asthma or chronic obstructive pulmonary disease (COPD).
  • In January 2019, CHIESI Farmaceutici S.p.A. entered into an exclusive global license agreement with TiumBio, a clinical-stage private biotech company based in South Korea. TiumBio specializes in research on innovative drugs for rare diseases. The agreement is aimed at developing innovative molecules for usage in the treatment of respiratory diseases.

Each of these players has been profiled in the chronic obstructive pulmonary disease (COPD) treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 19.8 Bn

Market Forecast Value in 2031

More than US$ 30.4 Bn

Growth Rate

4.4%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

Market share analysis by company (2021)

Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials.

Format

Electronic (PDF) + Excel

Market Segmentation

  • Drug Class
    • Combination Therapy
    • Bronchodilators
    • Corticosteroids
    • Phosphodiesterase Type 4 Inhibitor
    • Mucokinetics
    • Others
  • Type
    • Chronic Bronchitis
    • Emphysema
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Companies Profiled

  • Almirall
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • CHIESI Farmaceutici S.p.A.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Kyowa Hakko Kirin
  • Mylan N.V.
  • Novartis AG
  • Orion Corporation
  • Sanofi
  • Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.)
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma
  • Verona Pharmaceuticals

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global chronic obstructive pulmonary disease (COPD) treatment market in 2021?

The global chronic obstructive pulmonary disease (COPD) treatment market was valued at US$ 19.8 Bn in 2021.

How big will be the global chronic obstructive pulmonary disease (COPD) treatment market in 2031?

The global chronic obstructive pulmonary disease (COPD) treatment market is projected to reach more than US$ 30.4 Bn by 2031.

What will be the CAGR of the global chronic obstructive pulmonary disease (COPD) treatment market during the forecast period (2022–2031)?

The global chronic obstructive pulmonary disease (COPD) treatment market is anticipated to grow at a CAGR of 4.4% from 2022 to 2031.

Which are the prominent trends that affect market growth?

Rise in prevalence of chronic obstructive pulmonary disease (COPD) leading to an increase in demand for testing & diagnosis, surge in research & development activities, and growth in awareness about COPD.

What is the market share of the leading segment of the global chronic obstructive pulmonary disease (COPD) treatment market?

The combination therapy segment held around 55% share of the global market in 2021.

Which region will account for major share of the global market during the forecast period?

North America is expected to account for major share of the global chronic obstructive pulmonary disease (COPD) treatment market during the forecast period.

Who are the prominent players in the global chronic obstructive pulmonary disease (COPD) treatment market?

F. Hoffmann-La Roche Ltd., AstraZeneca, GlaxoSmithKline plc, Sanofi, Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Boehringer Ingelheim International GmbH, Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.)., CHIESI Farmaceutici S.p.A., Orion Corporation, Almirall, Theravance Biopharma, Verona Pharmaceuticals, and Kyowa Hakko Kirin.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlight

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definition

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, 2017–2031

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Regulatory Scenario by Region/globally

        5.2. Reimbursement Scenario by Region/globally

        5.3. Pipeline Analysis

        5.4. Technological Advancements

        5.5. Pricing Analysis (Brand pricing, Average Selling Price by Region/Country)

        5.6. Disease Prevalence & Incidence Rate globally with key countries

        5.7. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)

        5.8. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

    6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Drug Class

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Drug Class, 2017–2031

            6.3.1. Combination Therapy

                6.3.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

                6.3.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

                6.3.1.3. Triple therapy

                6.3.1.4. Others

            6.3.2. Bronchodilators

                6.3.2.1. Long Acting Beta Agonist (LABA)

                6.3.2.2. Short Acting Beta Agonist (SABA)

                6.3.2.3. Long Acting Muscarinic Antagonist (LAMA)

            6.3.3. Corticosteroids

            6.3.4. Phosphodiesterase Type 4 Inhibitor

            6.3.5. Mucokinetics

            6.3.6. Others

        6.4. Market Attractiveness Analysis, by Drug Class

    7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Type

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Type, 2017–2031

            7.3.1. Chronic Bronchitis

            7.3.2. Emphysema

        7.4. Market Attractiveness Analysis, by Type

    8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Distribution Channel, 2017–2031

            8.3.1. Hospital Pharmacies

            8.3.2. Retail Pharmacies

            8.3.3. Online Pharmacies

        8.4. Market Attractiveness Analysis, by Distribution Channel

    9. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Drug Class, 2017–2031

            10.2.1. Combination Therapy

                10.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

                10.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

                10.2.1.3. Triple therapy

                10.2.1.4. Others

            10.2.2. Bronchodilators

                10.2.2.1. Long Acting Beta Agonist (LABA)

                10.2.2.2. Short Acting Beta Agonist (SABA)

                10.2.2.3. Long Acting Muscarinic Antagonist (LAMA)

            10.2.3. Corticosteroids

            10.2.4. Phosphodiesterase Type 4 Inhibitor

            10.2.5. Mucokinetics

            10.2.6. Others

        10.3. Market Value Forecast, by Type, 2017–2031

            10.3.1. Chronic Bronchitis

            10.3.2. Emphysema

        10.4. Market Value Forecast, by Distribution Channel, 2017–2031

            10.4.1. Hospital Pharmacies

            10.4.2. Retail Pharmacies

            10.4.3. Online Pharmacies

        10.5. Market Value Forecast, by Country, 2017–2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Drug Class

            10.6.2. By Type

            10.6.3. By Distribution Channel

            10.6.4. By Country

    11. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Drug Class, 2017–2031

            11.2.1. Combination Therapy

                11.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

                11.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

                11.2.1.3. Triple therapy

                11.2.1.4. Others

            11.2.2. Bronchodilators

                11.2.2.1. Long Acting Beta Agonist (LABA)

                11.2.2.2. Short Acting Beta Agonist (SABA)

                11.2.2.3. Long Acting Muscarinic Antagonist (LAMA)

            11.2.3. Corticosteroids

            11.2.4. Phosphodiesterase Type 4 Inhibitor

            11.2.5. Mucokinetics

            11.2.6. Others

        11.3. Market Value Forecast, by Type, 2017–2031

            11.3.1. Chronic Bronchitis

            11.3.2. Emphysema

        11.4. Market Value Forecast, by Distribution Channel, 2017–2031

            11.4.1. Hospital Pharmacies

            11.4.2. Retail Pharmacies

            11.4.3. Online Pharmacies

        11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Spain

            11.5.5. Italy

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Drug Class

            11.6.2. By Type

            11.6.3. By Distribution Channel

            11.6.4. By Country/Sub-region

    12. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Drug Class, 2017–2031

            12.2.1. Combination Therapy

                12.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

                12.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

                12.2.1.3. Triple therapy

                12.2.1.4. Others

            12.2.2. Bronchodilators

                12.2.2.1. Long Acting Beta Agonist (LABA)

                12.2.2.2. Short Acting Beta Agonist (SABA)

                12.2.2.3. Long Acting Muscarinic Antagonist (LAMA)

            12.2.3. Corticosteroids

            12.2.4. Phosphodiesterase Type 4 Inhibitor

            12.2.5. Mucokinetics

            12.2.6. Others

        12.3. Market Value Forecast, by Type, 2017–2031

            12.3.1. Chronic Bronchitis

            12.3.2. Emphysema

        12.4. Market Value Forecast, by Distribution Channel, 2017–2031

            12.4.1. Hospital Pharmacies

            12.4.2. Retail Pharmacies

            12.4.3. Online Pharmacies

        12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Drug Class

            12.6.2. By Type

            12.6.3. By Distribution Channel

            12.6.4. By Country/Sub-region

    13. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Drug Class, 2017–2031

            13.2.1. Combination Therapy

                13.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

                13.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

                13.2.1.3. Triple therapy

                13.2.1.4. Others

            13.2.2. Bronchodilators

                13.2.2.1. Long Acting Beta Agonist (LABA)

                13.2.2.2. Short Acting Beta Agonist (SABA)

                13.2.2.3. Long Acting Muscarinic Antagonist (LAMA)

            13.2.3. Corticosteroids

            13.2.4. Phosphodiesterase Type 4 Inhibitor

            13.2.5. Mucokinetics

            13.2.6. Others

        13.3. Market Value Forecast, by Type, 2017–2031

            13.3.1. Chronic Bronchitis

            13.3.2. Emphysema

        13.4. Market Value Forecast, by Distribution Channel, 2017–2031

            13.4.1. Hospital Pharmacies

            13.4.2. Retail Pharmacies

            13.4.3. Online Pharmacies

        13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Drug Class

            13.6.2. By Type

            13.6.3. By Distribution Channel

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Drug Class, 2017–2031

            14.2.1. Combination Therapy

                14.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

                14.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

                14.2.1.3. Triple therapy

                14.2.1.4. Others

            14.2.2. Bronchodilators

                14.2.2.1. Long Acting Beta Agonist (LABA)

                14.2.2.2. Short Acting Beta Agonist (SABA)

                14.2.2.3. Long Acting Muscarinic Antagonist (LAMA)

            14.2.3. Corticosteroids

            14.2.4. Phosphodiesterase Type 4 Inhibitor

            14.2.5. Mucokinetics

            14.2.6. Others

        14.3. Market Value Forecast, by Type, 2017–2031

            14.3.1. Chronic Bronchitis

            14.3.2. Emphysema

        14.4. Market Value Forecast, by Distribution Channel, 2017–2031

            14.4.1. Hospital Pharmacies

            14.4.2. Retail Pharmacies

            14.4.3. Online Pharmacies

        14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Drug Class

            14.6.2. By Type

            14.6.3. By Distribution Channel

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competition Matrix (by tier and size of companies)

        15.2. Market Share Analysis, by Company, 2021

        15.3. Company Profiles

            15.3.1. F. Hoffmann-La Roche Ltd.

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Product Portfolio

                15.3.1.3. Financial Overview

                15.3.1.4. SWOT Analysis

                15.3.1.5. Strategic Overview

            15.3.2. AstraZeneca

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Product Portfolio

                15.3.2.3. Financial Overview

                15.3.2.4. SWOT Analysis

                15.3.2.5. Strategic Overview

            15.3.3. GlaxoSmithKline plc

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Product Portfolio

                15.3.3.3. Financial Overview

                15.3.3.4. SWOT Analysis

                15.3.3.5. Strategic Overview

            15.3.4. Sanofi

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Product Portfolio

                15.3.4.3. Financial Overview

                15.3.4.4. SWOT Analysis

                15.3.4.5. Strategic Overview

            15.3.5. Novartis AG

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Product Portfolio

                15.3.5.3. Financial Overview

                15.3.5.4. SWOT Analysis

                15.3.5.5. Strategic Overview

            15.3.6. Teva Pharmaceutical Industries Ltd.

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Product Portfolio

                15.3.6.3. Financial Overview

                15.3.6.4. SWOT Analysis

                15.3.6.5. Strategic Overview

            15.3.7. Mylan N.V.

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Product Portfolio

                15.3.7.3. Financial Overview

                15.3.7.4. SWOT Analysis

                15.3.7.5. Strategic Overview

            15.3.8. Boehringer Ingelheim International GmbH

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Product Portfolio

                15.3.8.3. Financial Overview

                15.3.8.4. SWOT Analysis

                15.3.8.5. Strategic Overview

            15.3.9. Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.)

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Product Portfolio

                15.3.9.3. Financial Overview

                15.3.9.4. SWOT Analysis

                15.3.9.5. Strategic Overview

            15.3.10. CHIESI Farmaceutici S.p.A.

                15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.10.2. Product Portfolio

                15.3.10.3. Financial Overview

                15.3.10.4. SWOT Analysis

                15.3.10.5. Strategic Overview

            15.3.11. Orion Corporation

                15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.11.2. Product Portfolio

                15.3.11.3. Financial Overview

                15.3.11.4. SWOT Analysis

                15.3.11.5. Strategic Overview

            15.3.12. Almirall

                15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.12.2. Product Portfolio

                15.3.12.3. Financial Overview

                15.3.12.4. SWOT Analysis

                15.3.12.5. Strategic Overview

            15.3.13. Theravance Biopharma

                15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.13.2. Product Portfolio

                15.3.13.3. Financial Overview

                15.3.13.4. SWOT Analysis

                15.3.13.5. Strategic Overview

            15.3.14. Verona Pharmaceuticals

                15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.14.2. Product Portfolio

                15.3.14.3. Financial Overview

                15.3.14.4. SWOT Analysis

                15.3.14.5. Strategic Overview

            15.3.15. Kyowa Hakko Kirin

                15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.15.2. Product Portfolio

                15.3.15.3. Financial Overview

                15.3.15.4. SWOT Analysis

                15.3.15.5. Strategic Overview

    List of Tables

    Table 01: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 02: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by 2017‒2031, by Combination Therapy

    Table 03: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by 2017‒2031, by Bronchodilators

    Table 04: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 05: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 06: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 07: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 08: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 09: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017‒2031

    Table 10: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017‒2031

    Table 11: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 12: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 13: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 15: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017‒2031

    Table 16: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017‒2031

    Table 17: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 18: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 19: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 20: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 21: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017‒2031

    Table 22: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017‒2031

    Table 23: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 24: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 25: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 26: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 27: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017‒2031

    Table 28: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017‒2031

    Table 29: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 30: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 31: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 32: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 33: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017‒2031

    Table 34: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017‒2031

    Table 35: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 36: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    List of Figures

    Figure 01: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share, by Drug Class, 2021

    Figure 03: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share, by Type, 2021

    Figure 04: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share, by Distribution Channel 2021

    Figure 05: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

    Figure 06: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

    Figure 07: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn), by Combination Therapy, 2017‒2031

    Figure 08: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn), by Bronchodilators, 2017‒2031

    Figure 09: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn), by Corticosteroids 2017‒2031

    Figure 10: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn), by Phosphodiesterase Type 4 Inhibitor, 2017‒2031

    Figure 11: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn), by Mucokinetics 2017‒2031

    Figure 12: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn), by Others, 2017‒2031

    Figure 13: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Type, 2021 and 2031

    Figure 14: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Type, 2022–2031

    Figure 15: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Chronic Bronchitis, 2017–2031

    Figure 16: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Emphysema, 2017–2031

    Figure 17: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 18: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 19: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031

    Figure 20: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031

    Figure 21: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Online Pharmacies, 2017–2031

    Figure 22: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Region, 2021 and 2031

    Figure 23: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Region, 2022–2031

    Figure 24: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 25: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country, 2021 and 2031

    Figure 26: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country, 2022–2031 

    Figure 27: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

    Figure 28: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

    Figure 29: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Type, 2021 and 2031

    Figure 30: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Type, 2022–2031

    Figure 31: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 32: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 33: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 34: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 35: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 36: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

    Figure 37: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

    Figure 38: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Type, 2021 and 2031

    Figure 39: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Type, 2022–2031

    Figure 40: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 41: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 42: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 43: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 44: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 45: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

    Figure 46: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

    Figure 47: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Type, 2021 and 2031

    Figure 48: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Type, 2022–2031

    Figure 49: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 50: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 51: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 52: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 53: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031

    Figure 54: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

    Figure 55: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

    Figure 56: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Type, 2021 and 2031

    Figure 57: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Type, 2022–2031

    Figure 58: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 59: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 60: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 61: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 62: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031

    Figure 63: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

    Figure 64: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

    Figure 65: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Type, 2021 and 2031

    Figure 66: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Type, 2022–2031

    Figure 67: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 68: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 69: Company Share Analysis, 2021

Copyright © Transparency Market Research, Inc. All Rights reserved